These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17923843)

  • 1. Tumor-targeted delivery of siRNA by self-assembled nanoparticles.
    Li SD; Chen YC; Hackett MJ; Huang L
    Mol Ther; 2008 Jan; 16(1):163-9. PubMed ID: 17923843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis.
    Yang Y; Li J; Liu F; Huang L
    Mol Ther; 2012 Mar; 20(3):609-15. PubMed ID: 22186791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.
    Chen Y; Sen J; Bathula SR; Yang Q; Fittipaldi R; Huang L
    Mol Pharm; 2009; 6(3):696-705. PubMed ID: 19267451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles.
    Li SD; Chono S; Huang L
    J Control Release; 2008 Feb; 126(1):77-84. PubMed ID: 18083264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
    Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
    Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor.
    Chono S; Li SD; Conwell CC; Huang L
    J Control Release; 2008 Oct; 131(1):64-9. PubMed ID: 18674578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells.
    Li SD; Huang L
    Mol Pharm; 2006; 3(5):579-88. PubMed ID: 17009857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery.
    Li J; Chen YC; Tseng YC; Mozumdar S; Huang L
    J Control Release; 2010 Mar; 142(3):416-21. PubMed ID: 19919845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain tumor-targeted therapy by systemic delivery of siRNA with Transferrin receptor-mediated core-shell nanoparticles.
    Wei L; Guo XY; Yang T; Yu MZ; Chen DW; Wang JC
    Int J Pharm; 2016 Aug; 510(1):394-405. PubMed ID: 27374198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.
    Yang Y; Hu Y; Wang Y; Li J; Liu F; Huang L
    Mol Pharm; 2012 Aug; 9(8):2280-9. PubMed ID: 22686936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy.
    Chen Y; Wu JJ; Huang L
    Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface-modified LPD nanoparticles for tumor targeting.
    Li SD; Huang L
    Ann N Y Acad Sci; 2006 Oct; 1082():1-8. PubMed ID: 17145918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
    Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
    Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
    Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
    Gujrati M; Vaidya AM; Mack M; Snyder D; Malamas A; Lu ZR
    Adv Healthc Mater; 2016 Nov; 5(22):2882-2895. PubMed ID: 27723260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.
    Li SD; Chono S; Huang L
    Mol Ther; 2008 May; 16(5):942-6. PubMed ID: 18388916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
    Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
    Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.
    Cho HJ; Chong S; Chung SJ; Shim CK; Kim DD
    Pharm Res; 2012 Apr; 29(4):1007-19. PubMed ID: 22169985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic siRNA delivery to tumors by cell-penetrating α-helical polypeptide-based metastable nanoparticles.
    Liu Y; Song Z; Zheng N; Nagasaka K; Yin L; Cheng J
    Nanoscale; 2018 Aug; 10(32):15339-15349. PubMed ID: 30070662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.